Savara (SVRA) Expected to Announce Quarterly Earnings on Thursday

Savara (NASDAQ:SVRA) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Savara to post earnings of ($0.11) per share for the quarter.

Savara Stock Performance

SVRA stock opened at $2.32 on Tuesday. The company has a market cap of $398.16 million, a P/E ratio of -5.40 and a beta of 0.63. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock’s fifty day moving average price is $2.84 and its 200-day moving average price is $3.47. Savara has a 1 year low of $2.31 and a 1 year high of $5.70.

Insider Buying and Selling at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.13% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Wells Fargo & Company assumed coverage on Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. Evercore ISI reiterated an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, HC Wainwright lowered their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.86.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.